{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T15:44:14Z","timestamp":1772034254959,"version":"3.50.1"},"reference-count":66,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Diffuse midline glioma (DMG) is a pediatric brain cancer that has a dismal prognosis with limited treatment options. We present the treatment course and outcome of an adolescent male diagnosed with a thalamic DMG carrying a histone H3.3 K27M (H3K27M) alteration. Tumor biopsies were taken at diagnosis for histological analysis, molecular profiling, and <jats:italic>ex vivo<\/jats:italic> drug sensitivity testing (DST). Seven months after diagnosis, the patient had recurrent\/progressive disease after radiotherapy and an ineffective molecular-guided therapy based on tumor molecular profiling. The patient then started a novel functional precision medicine (FPM)-guided two-drug combination of disulfiram, based on the DST results of this drug on the patient\u2019s tumor cells obtained at diagnosis, and ONC 201, the only drug that has advanced to a phase III clinical trial for H3K27M-DMG. Neuroimaging demonstrated a treatment response, and the patient lived for fifteen months after starting this personalized therapy. Disulfiram was discontinued after three months due to significant peripheral neuropathy. Our case describes the feasibility and limitations of using DST of patient-derived tumor cells to identify potentially effective personalized and novel therapies for DMG, which should be evaluated for efficacy and safety in formal N-of-1 clinical trials settings. We discuss the benefits and risks of this approach, particularly considering its use in children, adolescents, and young adults with pediatric brain cancers.<\/jats:p>","DOI":"10.3389\/fonc.2025.1606575","type":"journal-article","created":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T04:12:16Z","timestamp":1754539936000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Case Report: Application of ex-vivo drug sensitivity testing to identify personalized treatment options for an adolescent with diffuse midline glioma"],"prefix":"10.3389","volume":"15","author":[{"given":"Philip K.","family":"Tan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy J.","family":"Martins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela S.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J.","family":"Wechsler-Reya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John Ross","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.08.017","article-title":"Integrated molecular meta-analysis of 1,000 pediatric high-grade and diffuse intrinsic pontine glioma","volume":"32","author":"Mackay","year":"2017","journal-title":"Cancer Cell"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdaa142","article-title":"Clinical, radiologic, and genetic characteristics of histone H3 K27M-mutant diffuse midline gliomas in adults","volume":"2","author":"Schulte","year":"2020","journal-title":"Neurooncol Adv"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3171\/2024.8.JNS241180","article-title":"A comprehensive multicenter analysis of clinical, molecular, and imaging characteristics and outcomes of H3 K27-altered diffuse midline glioma in adults","volume":"142","author":"Sim","year":"2025","journal-title":"J Neurosurg"},{"key":"B4","doi-asserted-by":"publisher","first-page":"S92","DOI":"10.1093\/neuonc\/noad164","article-title":"H3K27M mutant glioma: Disease definition and biological underpinnings","volume":"26","author":"Saratsis","year":"2024","journal-title":"Neuro Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15194869","article-title":"Decoding diffuse midline gliomas: A comprehensive review of pathogenesis, diagnosis and treatment","volume":"15","author":"Al Sharie","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26988","article-title":"Reirradiation in patients with diffuse intrinsic pontine gliomas: The Canadian experience","volume":"65","author":"Lassaletta","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1182994","article-title":"Neurological symptom improvement after re-irradiation in patients with diffuse intrinsic pontine glioma: A retrospective analysis of the SIOP-E-HGG\/DIPG project","volume":"12","author":"Chavaz","year":"2022","journal-title":"Front Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1038\/s41591-024-02848-4","article-title":"Feasibility of functional precision medicine for guiding treatment of relapsed or refractory pediatric cancers","volume":"30","author":"Acanda de la Rocha","year":"2024","journal-title":"Nat Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-0538","article-title":"Functional precision medicine provides clinical benefit in advanced aggressive hematologic cancers and identifies exceptional responders","volume":"12","author":"Kornauth","year":"2022","journal-title":"Cancer Discov"},{"key":"B10","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1158\/2159-8290.CD-21-0410","article-title":"Implementing a functional precision medicine tumor board for acute myeloid leukemia","volume":"12","author":"Malani","year":"2022","journal-title":"Cancer Discov"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/PO.20.00438","article-title":"Clinical utility of functional precision medicine in the management of recurrent\/relapsed childhood rhabdomyosarcoma","volume":"5","author":"Acanda de la Rocha","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/PO.20.00442","article-title":"High-throughput drug screening and multi-omic analysis to guide individualized treatment for multiple myeloma","volume":"5","author":"Coffey","year":"2021","journal-title":"JCO Precis Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.leukres.2017.11.008","article-title":"Ex-vivo sensitivity profiling to guide clinical decision making in acute myeloid leukemia: A pilot study","volume":"64","author":"Swords","year":"2018","journal-title":"Leuk Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noae031","article-title":"ACTION: a randomized phase 3 study of ONC201 (dordaviprone) in patients with newly diagnosed H3 K27M-mutant diffuse glioma","volume":"26","author":"Arrillaga-Romany","year":"2024","journal-title":"Neuro Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noae064.166","article-title":"TRLS-13. MULTI-OMICS AND FUNCTIONAL PRECISION MEDICINE FOR NEWLY DIAGNOSED AND RECURRENT PEDIATRIC CENTRAL NERVOUS SYSTEM TUMORS","volume":"26","author":"Crawford","year":"2024","journal-title":"Neuro Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-1674","article-title":"Mutation patterns predict drug sensitivity in acute myeloid leukemia","volume":"30","author":"Qin","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw0064","article-title":"Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening","volume":"11","author":"Lin","year":"2019","journal-title":"Sci Transl Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3855","article-title":"Functionally defined therapeutic targets in diffuse intrinsic pontine glioma","volume":"21","author":"Grasso","year":"2015","journal-title":"Nat Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.933655","article-title":"Disulfiram in glioma: Literature review of drug repurposing","volume":"13","author":"Zhong","year":"2022","journal-title":"Front Pharmacol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noz022","article-title":"Molecular profiling and targeted therapy in pediatric gliomas: review and consensus recommendations","volume":"21","author":"Miklja","year":"2019","journal-title":"Neuro Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdab169","article-title":"Preclinical and clinical evaluation of German-sourced ONC201 for the treatment of H3K27M-mutant diffuse intrinsic pontine glioma","volume":"3","author":"Duchatel","year":"2021","journal-title":"Neurooncol Adv"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-016-2104-2","article-title":"A phase I study to repurpose disulfiram in combination with temozolomide to treat newly diagnosed glioblastoma after chemoradiotherapy","volume":"128","author":"Huang","year":"2016","journal-title":"J Neurooncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-018-2775-y","article-title":"Final results of a phase I dose-escalation, dose-expansion study of adding disulfiram with or without copper to adjuvant temozolomide for newly diagnosed glioblastoma","volume":"138","author":"Huang","year":"2018","journal-title":"J Neurooncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1017\/S0790966700010454","article-title":"Disulfiram induced peripheral neuropathy: between the devil and the deep blue sea","volume":"24","author":"Behan","year":"2007","journal-title":"Ir J Psychol Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0773.2001.088002106.x","article-title":"Differentiation of disulfiram effects on central catecholamines and hepatic ethanol metabolism","volume":"88","author":"Karamanakos","year":"2001","journal-title":"Pharmacol Toxicol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.53.3.227","article-title":"Peripheral nerve functions in chronic alcoholic patients on disulfiram: a six month follow up","volume":"53","author":"Palliyath","year":"1990","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.alcalc.a044938","article-title":"Disulfiram neuropathy: a review (1971-1988) and report of a case","volume":"24","author":"Frisoni","year":"1989","journal-title":"Alcohol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.31.6.730","article-title":"Disulfiram neuropathy","volume":"31","author":"Mokri","year":"1981","journal-title":"Neurology"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1080\/0959523031000154436","article-title":"Comparison of disulfiram and placebo in treatment of alcohol dependence of adolescents","volume":"22","author":"Niederhofer","year":"2003","journal-title":"Drug Alcohol Rev"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdac143","article-title":"Phase I dose escalation and expansion trial of single agent ONC201 in pediatric diffuse midline gliomas following radiotherapy","volume":"4","author":"Gardner","year":"2022","journal-title":"Neurooncol Adv"},{"key":"B31","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s40425-019-0599-8","article-title":"Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration","volume":"7","author":"Stein","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-022-01236-3","article-title":"The landscape of tumor cell states and spatial organization in H3-K27M mutant diffuse midline glioma across age and location","volume":"54","author":"Liu","year":"2022","journal-title":"Nat Genet"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1186\/s40478-015-0269-0","article-title":"Spatial genomic heterogeneity in diffuse intrinsic pontine and midline high-grade glioma: implications for diagnostic biopsy and targeted therapeutics","volume":"4","author":"Hoffman","year":"2016","journal-title":"Acta Neuropathol Commun"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11185","article-title":"Spatial and temporal homogeneity of driver mutations in diffuse intrinsic pontine glioma","volume":"7","author":"Nikbakht","year":"2016","journal-title":"Nat Commun"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1219747110","article-title":"Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics","volume":"110","author":"Sottoriva","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1172\/JCI170329","article-title":"PI3K\/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma","volume":"134","author":"Duchatel","year":"2024","journal-title":"J Clin Invest"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01134","article-title":"ONC201 (Dordaviprone) in recurrent H3 K27M-mutant diffuse midline glioma","volume":"42","author":"Arrillaga-Romany","year":"2024","journal-title":"J Clin Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-23-0131","article-title":"Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways","volume":"13","author":"Venneti","year":"2023","journal-title":"Cancer Discov"},{"key":"B39","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1093\/neuonc\/noz164","article-title":"Biological activity of weekly ONC201 in adult recurrent glioblastoma patients","volume":"22","author":"Arrillaga-Romany","year":"2020","journal-title":"Neuro\u00a0Oncol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s11060-019-03271-3","article-title":"Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201","volume":"145","author":"Chi","year":"2019","journal-title":"J Neurooncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3171\/2019.2.PEDS18480","article-title":"First clinical experience with DRD2\/3 antagonist ONC201 in H3 K27M-mutant pediatric diffuse intrinsic pontine glioma: a case report","volume":"23","author":"Hall","year":"2019","journal-title":"J Neurosurg Pediatr"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2023.100931","article-title":"Histone H3 K27M-mediated regulation of cancer cell stemness and differentiation in diffuse midline glioma","volume":"44","author":"Sharma","year":"2023","journal-title":"Neoplasia"},{"key":"B43","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/s41419-021-04078-9","article-title":"Alcohol-abuse drug disulfiram targets pediatric glioma via MLL degradation","volume":"12","author":"Meier","year":"2021","journal-title":"Cell\u00a0Death Dis"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2014-0424","article-title":"A phase IIb trial assessing the addition of disulfiram to chemotherapy for the treatment of metastatic non-small cell lung cancer","volume":"20","author":"Nechushtan","year":"2015","journal-title":"Oncologist"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.4149","article-title":"Effect of disulfiram and copper plus chemotherapy vs chemotherapy alone on survival in patients with recurrent glioblastoma: A randomized clinical trial","volume":"6","author":"Werlenius","year":"2023","journal-title":"JAMA Netw Open"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12030524","article-title":"Disulfiram: mechanisms, applications, and challenges","volume":"12","author":"Lanz","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15061567","article-title":"Advancing cancer therapy with copper\/disulfiram nanomedicines and drug delivery systems","volume":"15","author":"Kang","year":"2023","journal-title":"Pharmaceutics"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noae001","article-title":"Safety and pharmacokinetics of ONC201 (dordaviprone) administered two consecutive days per week in pediatric patients with H3 K27M-mutant glioma","volume":"26","author":"Odia","year":"2024","journal-title":"Neuro Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noad144","article-title":"A review of current therapeutics targeting the mitochondrial protease ClpP in diffuse midline glioma, H3 K27-altered","volume":"26","author":"Jackson","year":"2024","journal-title":"Neuro Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-23-0186","article-title":"ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma","volume":"83","author":"Jackson","year":"2023","journal-title":"Cancer Res"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noad141","article-title":"Phase I trial of panobinostat in children with diffuse intrinsic pontine glioma: A report from the Pediatric Brain Tumor Consortium (PBTC-047)","volume":"25","author":"Monje","year":"2023","journal-title":"Neuro Oncol"},{"key":"B53","unstructured":"Secura bio, inc.; withdrawal of approval of new drug application for FARYDAK (Panobinostat) capsules, 10 milligrams, 15 milligrams, and 20 milligrams\n          \n          \n          \n          2022"},{"key":"B54","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N Engl J Med"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/nature25480","article-title":"The landscape of genomic alterations across childhood cancers","volume":"555","author":"Gr\u00f6bner","year":"2018","journal-title":"Nature"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/nature25795","article-title":"Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours","volume":"555","author":"Ma","year":"2018","journal-title":"Nature"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-023-02609-6","article-title":"A comprehensive genomic study of 390 H3F3A-mutant pediatric and adult diffuse high-grade gliomas, CNS WHO grade 4","volume":"146","author":"Williams","year":"2023","journal-title":"Acta Neuropathol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdad040","article-title":"Pediatric diffuse midline glioma: Understanding the mechanisms and assessing the next generation of personalized therapeutics","volume":"5","author":"Jovanovich","year":"2023","journal-title":"Neurooncol Adv"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-024-02800-3","article-title":"Integrated analyses reveal two molecularly and clinically distinct subtypes of H3 K27M-mutant diffuse midline gliomas with prognostic significance","volume":"148","author":"Stegat","year":"2024","journal-title":"Acta Neuropathol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02379-4","article-title":"The NCI-MATCH trial: lessons for precision oncology","volume":"29","author":"O\u2019Dwyer","year":"2023","journal-title":"Nat Med"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.04.003","article-title":"Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020","volume":"32","author":"Haslam","year":"2021","journal-title":"Ann Oncol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-0803","article-title":"Upfront biology-guided therapy in diffuse intrinsic pontine glioma: therapeutic, molecular, and biomarker outcomes from PNOC003","volume":"28","author":"Kline","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.113359","article-title":"At the right dose: personalised (N-of-1) dosing for precision oncology","volume":"194","author":"Nikanjam","year":"2023","journal-title":"Eur J Cancer"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-22-1377","article-title":"N-of-1 trials in cancer drug development","volume":"13","author":"Gouda","year":"2023","journal-title":"Cancer Discov"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13215428","article-title":"N-of-1 trials in pediatric oncology: from a population-based approach to personalized medicine-A review","volume":"13","author":"Kyr","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15123199","article-title":"Repurposing of chronically used drugs in cancer therapy: A chance to grasp","volume":"15","author":"Hijazi","year":"2023","journal-title":"Cancers (Basel)"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1606575\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T04:12:18Z","timestamp":1754539938000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1606575\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,7]]},"references-count":66,"alternative-id":["10.3389\/fonc.2025.1606575"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1606575","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,7]]},"article-number":"1606575"}}